Squarepoint Ops LLC Increases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Squarepoint Ops LLC lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 64.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 353,196 shares of the biotechnology company’s stock after purchasing an additional 138,970 shares during the period. Squarepoint Ops LLC owned about 0.15% of ADMA Biologics worth $3,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Eagle Asset Management Inc. increased its stake in shares of ADMA Biologics by 20.2% in the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 4,367 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its stake in shares of ADMA Biologics by 19.2% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 143,424 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 23,127 shares in the last quarter. Prism Advisors Inc. purchased a new stake in shares of ADMA Biologics in the first quarter worth $128,000. EWG Elevate Inc. increased its stake in shares of ADMA Biologics by 100.0% in the first quarter. EWG Elevate Inc. now owns 100,000 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Viewpoint Capital Management LLC increased its stake in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 2,416 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares of the company’s stock, valued at $7,589,587.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 over the last 90 days. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ADMA shares. HC Wainwright upped their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Mizuho upped their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Price Performance

ADMA stock opened at $19.77 on Wednesday. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $20.37. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The company has a fifty day simple moving average of $16.51 and a two-hundred day simple moving average of $11.56. The firm has a market capitalization of $4.58 billion, a P/E ratio of -988.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter last year, the business earned ($0.02) earnings per share. ADMA Biologics’s quarterly revenue was up 78.4% compared to the same quarter last year. Analysts anticipate that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.